The dosing mishap was presented to the trial participants in a letter dated June 8 as an opportunity for University of Oxford researchers to learn how well the vaccine works at different doses. The letter was signed by the trial's chief investigator, Oxford professor Andrew J. Pollard
Poonawalla'' remarks came soon after after India's drugs regulator, Drug Controller General of India (DCGI) approved Covishield for restricted emergency use.
An expert panel on COVID-19 of the Central Drugs Standard Control Organisation (CDSCO) on Friday recommended to grant emergency use authorisation for the Oxford COVID-19 vaccine Covishield, being manufactured by Serum Institute of India, sources said on Friday.
Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, is manufacturing a version of the Oxford-AstraZeneca Covid-19 vaccine "Covishield" in India.
The coronavirus vaccine developed by Oxford University and AstraZeneca should be effective against the highly transmissible new strain of the virus, a UK media report said on Sunday.
With preparations underway for a possible vaccine-rollout by January, the Indian drug regulator is looking at the UK, which sources believe may give its nod to the Oxford COVID-19 vaccine next week, before deciding on giving emergency use authorisation to the Serum Institute that is manufacturing the shots here.
The Oxford University vaccine against COVID-19 being produced by AstraZeneca is likely to get regulatory approval from the UK’s independent regulator by the end of this year for a rollout to begin in early 2021, according to a UK media report.
Oxford University on Thursday said that its COVID-19 vaccine candidate has a better immune response when a two full-dose regime is used rather than a full-dose followed by a half-dose booster.
The Oxford University and AstraZeneca COVID-19 vaccine, currently awaiting regulatory approvals, is set to be used for a “mix and match” trial with Russia’s Sputnik vaccine against the novel coronavirus, according to UK media reports.
Australian Ambassador to India Barry O'Farrell lauded the country's effort on development of a vaccine against coronavirus saying, "There're many vaccines being produced in countries around the world but there's only one country that has the manufacturing capacity to produce sufficient quantities to satisfy the demands of citizens in every country & that's India."
The UK government said on Friday that it has formally asked the country's independent medicines regulator to assess the suitability of Oxford-AstraZeneca’s COVID-19 vaccine for temporary supply, as soon as the company submits the necessary safety, quality and efficacy data.
Vaccine major Serum Institute of India on Thursday said the COVID-19 vaccine developed by AstraZeneca and Oxford University is safe and effective, and the Indian trials are progressing smoothly with strict adherence to all protocols.
The Indian economy is seen recovering faster than expected and the Reserve Bank is likely to have come to an end of the rate easing cycle, according to global forecasting firm Oxford Economics.
Serum Institute of India, the world's largest vaccine maker, is ramping up production of AstraZeneca's Covid-19 shot to have 100 million doses ready by December for an inoculation drive expected to begin across India that same month.
Oxford-AstraZeneca coronavirus vaccine, one of the leading vaccine candidates out there and undergoing final stage phase 3 clinical trials, is producing immune response in young and old adults.
The Oxford University-developed coronavirus vaccine could be rolled out within three months in the UK, news agency IANS quoted the Times as saying.
The Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, has administered the first dose of Oxford Covid-19 vaccine -- Covishield -- to three candidates on Friday, informed PGI Chandigarh Director Prof Jagat Ram.
Just as biopharmaceutical giant AstraZeneca and the University of Oxford on Saturday announced that clinical trials for their coronavirus vaccine have resumed in the UK, Adar Poonawalla advised all to not jump to conclusions until completion of the process. Poonawalla is the chief executive officer of the vaccine's local manufacturer Serum Institute of India (SII).
The Serum Institute of India (SII), which is conducting Oxford-AstraZeneca coronavirus vaccine phase 2 and 3 trials in India, has received a show-cause notice from the central drug regulator for not informing it about pharma giant AstraZeneca pausing the clinical trials of the Oxford vaccine candidate in other countries and also for not submitting casualty analysis of the "reported serious adverse events".
The Serum Institute of India (SII), which is conducting Oxford-AstraZeneca coronavirus vaccine phase 2-3 trials in India, has said that the Indian trials of the vaccine are continuing and they can't comment on the UK trials which have been paused after a patient developed unexplained illness.
Top News
Latest News
